Quince Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 32
- Market Cap
- $29.8M
- Website
- http://quincetx.com
- Introduction
Quince Therapeutics, Inc.(formerly Cortexyme, Inc.） is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline composed of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
Quince Therapeutics' Phase 3 NEAT Trial for Ataxia-Telangiectasia Reaches 50% Enrollment Milestone
• Quince Therapeutics has enrolled 46 participants in its Phase 3 NEAT trial evaluating EryDex for Ataxia-Telangiectasia treatment, with completion expected in Q2 2025 and topline results by year-end.
• The pivotal trial, conducted under FDA Special Protocol Assessment, aims to enroll 86 patients aged 6-9 years and 20 patients aged 10 or older to evaluate EryDex's neurological effects.
• An open-label extension study has been initiated with 17 participants from the U.S., U.K., and European Union already transitioning from the main trial.
Quince Therapeutics Presents Phase 3 ATTeST Trial Safety Data for EryDex in Ataxia-Telangiectasia
• Quince Therapeutics presented safety data from the Phase 3 ATTeST trial of EryDex for Ataxia-Telangiectasia (A-T) at the Child Neurology Society Annual Meeting.
• The study found EryDex was generally well-tolerated, with most treatment-emergent adverse events (TEAEs) being mild to moderate and transient, similar to placebo.
• Typical steroid-related side effects were not observed, suggesting a favorable safety profile for intra-erythrocyte dexamethasone sodium phosphate.
• Quince is currently enrolling patients in the pivotal Phase 3 NEAT trial, with topline results expected in the fourth quarter of 2025.
EryDex Shows Long-Term Safety in Pediatric Ataxia-Telangiectasia Patients
• Quince Therapeutics' EryDex demonstrates a favorable long-term safety profile in pediatric patients with Ataxia-Telangiectasia (A-T) over a minimum of 24 months.
• The study reported infrequent occurrences of adverse events typically associated with prolonged glucocorticoid use, such as Cushingoid features or stunted growth.
• Quince is currently enrolling patients in the pivotal Phase 3 NEAT trial, with topline results expected in Q4 2025, potentially leading to regulatory submissions in 2026.
© Copyright 2025. All Rights Reserved by MedPath